Publikationsliste SFB824 Projekt C8


1. Grünwald, G.K., et al., Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus. Gene Ther, 2013. 20(6): p. 625-33.

2. Grünwald, G.K., et al., EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Mol Ther Nucleic Acids, 2013. 2(11): p. e131.

3. Grünwald, G.K., et al., Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene. J Nucl Med, 2013. 54(8): p. 1450-7.

4. Klutz, K., et al., Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin Cancer Res, 2009. 15(19): p. 6079-86.

5. Klutz, K., et al., Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther, 2011. 19(4): p. 676-85.

6. Klutz, K., et al., Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Hum Gene Ther, 2011. 22(12): p. 1563-74.

7. Klutz, K., et al., Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum Gene Ther, 2011. 22(11): p. 1403-12.

8. Knoop, K., et al., Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther, 2011. 19(9): p. 1704-13.

9. Knoop, K., et al., Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Hum Gene Ther, 2013. 24(3): p. 306-16.

10. Knoop, K., et al., Mesenchymal stem cell-mediated, tumor stroma-targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene. J Nucl Med, 2015. 56(4): p. 600-6.

11. Schug, C., et al., A Novel Approach for Image-Guided (131)I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. Mol Cancer Res, 2019. 17(1): p. 310-320.

12. Schug, C., et al., Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell-Mediated Sodium Iodide Symporter (NIS) Gene (131)I Therapy. Clin Cancer Res, 2019. 25(19): p. 5997-6008.

13. Schug, C., et al., External Beam Radiation Therapy Enhances Mesenchymal Stem Cell-Mediated Sodium-Iodide Symporter Gene Delivery. Hum Gene Ther, 2018. 29(11): p. 1287-1300.

14. Schug, C., et al., TGFB1-driven mesenchymal stem cell-mediated NIS gene transfer. Endocr Relat Cancer, 2019. 26(1): p. 89-101.

15. Urnauer, S., et al., Systemic tumor-targeted sodium iodide symporter (NIS) gene therapy of hepatocellular carcinoma mediated by B6 peptide polyplexes. J Gene Med, 2017. 19(5).

16. Urnauer, S., et al., Sequence-defined cMET/HGFR-targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter (NIS) Gene. Mol Ther, 2016. 24(8): p. 1395-404.

17. Urnauer, S., et al., EGFR-targeted nonviral NIS gene transfer for bioimaging and therapy of disseminated colon cancer metastases. Oncotarget, 2017. 8(54): p. 92195-92208.

18. Urnauer, S., et al., Dual-targeted NIS polyplexes-a theranostic strategy toward tumors with heterogeneous receptor expression. Gene Ther, 2019. 26(3-4): p. 93-108.

19. Müller, A.M., et al., Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery. Oncotarget, 2016. 7(34): p. 54795-54810.

20. Schmohl, K.A., et al., Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma. Thyroid, 2017. 27(12): p. 1534-1543.

21. Schmohl, K.A., et al., Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene. Oncotarget, 2017. 8(20): p. 33393-33404.

22. Schmohl, K.A., et al., Thyroid hormones and tetrac: new regulators of tumour stroma formation via integrin αvβ3. Endocr Relat Cancer, 2015. 22(6): p. 941-52.

23. Schmohl, K.A., et al., Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice. Eur Thyroid J, 2015. 4(Suppl 1): p. 74-80.

24. Schmohl, K.A., et al., Integrin αvβ3-dependent thyroid hormone effects on tumour proliferation and vascularisation. Endocr Relat Cancer, 2020. 27(12): p. 685-697.

25. Schmohl, K.A., et al., Integrin αvβ3-Mediated Effects of Thyroid Hormones on Mesenchymal Stem Cells in Tumor Angiogenesis. Thyroid, 2019. 29(12): p. 1843-1857.

26. Tutter, M., et al., Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy. Mol Ther, 2021. 29(2): p. 788-803.

27. Tutter, M., et al., Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells. Theranostics, 2020. 10(10): p. 4490-4506.

Katys Reviews?

28. Schmohl, K.A., et al., Thyroid Hormone Effects on Mesenchymal Stem Cell Biology in the Tumour Microenvironment. Exp Clin Endocrinol Diabetes, 2020. 128(6-07): p. 462-468.

29. Schmohl, K.A., P.J. Nelson, and C. Spitzweg, Tetrac as an anti-angiogenic agent in cancer. Endocr Relat Cancer, 2019. 26(6): p. R287-r304.